EXTON, Pa.--(BUSINESS WIRE)--Morphotek, Inc., a subsidiary of Eisai Co., Ltd. announced today the issuance of United States Patent No. 7,235,643 B2 (the “643” patent). The patent relates to certain methods of enhancing the affinity of monoclonal antibodies (mAbs). It illustrates the company’s MORPHODOMA® technology, a whole genome evolution platform that can enhance cells producing mAbs to yield daughter cells producing antibodies with enhanced pharmacologic activity. MORPHODOMA® technology enhances evolution within cells through the reversible regulation of the mismatch repair (MMR) pathway, a highly conserved process employed by all living organisms to repair mutations that naturally occur during DNA replication.
